The CasPlus Gene Editing Platform Technology can Correct Mutations Associated with Duchenne’s Muscular Dystrophy and Cystic Fibrosis with High Efficiency and Exceptionally Low Rates of On-Target DNA Damages
- Tuesday, May 17, 2022, 7:22
- Business
- Add a comment
NEW YORK, May 17, 2022 /PRNewswire/ — SCRIPT BIOSCIENCES INC, a biotechnology company developing curative therapies using a novel gene editing platform (CasPlus), and NYU Grossman School of Medicine, presented a poster titled “Enhancement of Predictable and Template-free Gene Editing by…
About the Author
adminasapcorp has written 41616 stories on this site.